Eric Klawiter, MD
Neurology · Boston, MANPI 1982874046
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,079 of the $40,624 with a category attached, or 81.4%. 10 manufacturers reported payments, led by Genentech USA, Inc. at 31.3% of the total. 2025 is the largest year on record at $14,458, more than ten times the $116 reported in 2019. Among neurology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $1562.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$13K
- TG Therapeutics, Inc.$9K
- Sanofi$7K
- EMD Serono, Inc.$5K
- UCB SA$3K
- Greenwich Biosciences, Inc.$3K
- plus $1K from 4 others
Across 107 payments — averaging $8313.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$332K
- AbbVie$283K
- Biogen$148K
- F. Hoffmann-la Roche AG$126K
What the payments were for
- Consulting fees$33,07981%
- Speaking & faculty fees$2,8407%
- Travel & lodging$3,7619%
- Food & beverage$9242%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 7 | $12,707 |
| TG Therapeutics, Inc. | 5 | $9,243 |
| Sanofi | 2 | $6,941 |
| EMD Serono, Inc. | 6 | $4,787 |
| UCB SA | 1 | $3,200 |
| Greenwich Biosciences, Inc. | 1 | $2,618 |
| Banner Life Sciences, LLC | 1 | $900 |
| AstraZeneca | 1 | $116 |
| Amgen | 1 | $92 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIUMVI$7,303
- Evobrutinib$4,400
- OCREVUS$2,895
- Enspryng$2,295
- Bafiertam$900
How this compares
$40,624 in reported general payments places this provider in the 90th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 47 | $330,956 |
| Kesimpta PenOfatumumab | 11 | $203,792 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 11 | $114,761 |
| Glatiramer Acetate | 28 | $96,153 |
| GlatopaGlatiramer Acetate | 35 | $62,456 |
| Dimethyl Fumarate | 51 | $61,574 |
| Dalfampridine ErDalfampridine | 30 | $26,264 |
| Gabapentin | 108 | $3,444 |
| Modafinil | 43 | $3,286 |
| Baclofen | 85 | $2,000 |
| Tizanidine Hcl | 15 | $481 |
| Pregabalin | 17 | $358 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Roy FreemanBoston$390K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.